Actinium Pharmaceuticals, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ATNM NYSE American 2836 www.actiniumpharma.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Actinium Pharmaceuticals, Inc.

Actinium: Q3 Earnings Snapshot - Nov 14th, 2025 3:01 pm
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications - Nov 4th, 2025 5:30 am
Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference - Nov 3rd, 2025 6:30 am
Actinium Announces Superior Anti-Tumor Activity of ATNM-400 in Lung Cancer Compared to the Leading First, Second and Third-Line Approved EGFR Mutant Therapies and Mechanistic Synergy with Osimertinib at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 27th, 2025 5:00 am
Actinium Pharmaceuticals Presents New Data Demonstrating Potent and Durable Efficacy of ATNM-400, a First-in-Class Multi-Tumor Actinium-225 Radiotherapy, at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - Oct 24th, 2025 6:30 am
Sector Update: Health Care Stocks Advance Monday Afternoon - Oct 13th, 2025 11:42 am
Actinium Pharmaceuticals to Unveil the Multi-Tumor Potential of ATNM-400, a First-in-Class Actinium-225 Radiotherapy, with Data in Non-Small Cell Lung Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - Oct 13th, 2025 10:10 am
Actinium to Present ATNM-400 Preclinical Data Highlighting Durable Tumor Control and Ability to Overcome Resistance to Standard-of-Care Prostate Cancer Therapies at the 32nd Annual Prostate Cancer Foundation Scientific Retreat - Oct 13th, 2025 6:30 am
Is Armata Pharmaceuticals (ARMP) Stock Outpacing Its Medical Peers This Year? - Sep 18th, 2025 7:40 am
Is Actinium Pharmaceuticals (ATNM) Stock Outpacing Its Medical Peers This Year? - Sep 2nd, 2025 7:40 am
Actinium: Q2 Earnings Snapshot - Aug 8th, 2025 3:15 pm
Actinium Presents Data Supporting Paradigm Changing Potential of ATNM-400 in Prostate Cancer Demonstrating Its Superior Efficacy and Improved Survival in Treatment Resistant Tumor Models versus Pluvicto and ARPI Therapy, and Also Enhanced Efficacy in Combination with ARPI Therapy at the 4th Annual Targeted Radiopharmaceuticals Summit - Jul 31st, 2025 6:30 am
Actinium Highlights ATNM 400 Progress at SNMMI Conference - Jul 2nd, 2025 8:05 pm
Actinium Highlights Expanded Data Set for ATNM-400 in Prostate Cancer Demonstrating Superior Efficacy to Enzalutamide and Ability to Overcome Resistance to ARPI Therapy and PSMA-Ac-225/Lu-177 Labelled Radiotherapy at the Society of Nuclear Medicine & Molecular Imaging Annual Meeting - Jun 23rd, 2025 9:30 am
Life Sciences Investor Forum: Now Available for Online Viewing - Jun 13th, 2025 6:35 am
Life Sciences Investor Forum Agenda Announced for June 11th-12th - Jun 10th, 2025 12:38 pm
Actinium: Q1 Earnings Snapshot - May 9th, 2025 3:33 pm
Actinium Announces Enrollment of First Patient in the Iomab-ACT Commercial CAR-T Trial at the University of Texas Southwestern Medical Center - May 6th, 2025 6:45 am
Actinium Presents Data Showing ATNM-400 is More Efficacious than Pluvicto and is Highly Efficacious after Pluvicto Resistance in Prostate Cancer Tumor Models at the American Association for Cancer Research Annual Meeting - Apr 28th, 2025 6:30 am
Actinium Highlights Mutation Agnostic Antileukemic Activity of Actimab-A Against FLT3, NPM1, KMT2A and TP53 Mutations in AML Models Demonstrating Backbone Potential for Acute Myeloid Leukemia Treatment at the American Association for Cancer Research Annual Meeting - Apr 28th, 2025 6:00 am